Benign Prostatic Hyperplasia and Lower Urinary Tract SymptomsIndividualized Management in Primary Care
Baseline Factors as Predictors of Clinical Progression of Benign Prostatic Hyperplasia in Men Treated With Placebo
Crawford ED, et al. J Urol. 2006;175:1422-1426.
The Correlation Between Metabolic Syndrome and Prostatic Diseases
De Nunzio C, et al. Eur Urol. 2012;61:560-570.
A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with α-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Gacci M, et al. Eur Urol. 2012;61:994-1003.
The Mechanism of Action of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia
Giuliano F, et al. Eur Urol. 2013;63:506-516.
Laborde EE, McVary KT. Rev Urol. 2009;11(suppl 1):S19-S25.
Roehrborn CG. Rev Urol. 2009;11(suppl 1):S1-S8.
The Effect of Benign Lower Urinary Tract Symptoms on Subsequent Prostate Cancer Testing and Diagnosis
Weight CJ, et al. Eur Urol. 2013;63:1021-1027.
A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting
Rosenberg MT, et al. Int J Clin Pract. 2007;61:1535-1546.
Scientific and Clinical Insights Into Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms
Steven A. Kaplan, MD
Best Practices in Diagnosis and Management